Bristol-Myers Squibb Co. (BMY)

50.88
3.42 6.30
NYSE : Health Technology
Prev Close 54.30
Open 51.25
Day Low/High 50.51 / 51.90
52 Wk Low/High 49.96 / 70.05
Volume 24.62M
Avg Volume 5.87M
Exchange NYSE
Shares Outstanding 1.63B
Market Cap 91.35B
EPS 0.60
P/E Ratio 233.25
Div & Yield 1.60 (2.70%)
Where the Bears Are: Cramer's 'Mad Money' Recap (Tuesday 5/15/18)

Where the Bears Are: Cramer's 'Mad Money' Recap (Tuesday 5/15/18)

Get ahead of the naysayers, says Jim Cramer. FANG and other tech leaders have gone cold, but they're not dead yet.

Bristol-Myers Squibb To Take Part In UBS 2018 Global Healthcare Conference

Bristol-Myers Squibb To Take Part In UBS 2018 Global Healthcare Conference

Bristol-Myers Squibb Company (NYSE:BMY) will take part in the UBS 2018 Global Healthcare Conference on Tuesday, May 22, 2018, in New York.

Being Bullish on Trump Surprisingly Worked Well for Investors This Week

Being Bullish on Trump Surprisingly Worked Well for Investors This Week

President Trump reduced tensions in Korea, raised them in the Middle East, and mainly relieved them for investors in the drug and healthcare industries.

Surveying the M&A Landscape in Biotech

Surveying the M&A Landscape in Biotech

Who might be in play in the quarters ahead?

European Medicines Agency Validates Bristol-Myers Squibb's Type II Variation Application For Opdivo Plus Yervoy Combination For Treatment Of First-Line Metastatic Non-Small Cell Lung Cancer (NSCLC)

European Medicines Agency Validates Bristol-Myers Squibb's Type II Variation Application For Opdivo Plus Yervoy Combination For Treatment Of First-Line Metastatic Non-Small Cell Lung Cancer (NSCLC)

Bristol-Myers Squibb Company (NYSE: BMY) today announced that the European Medicines Agency (EMA) validated a type II variation application for the Opdivo (nivolumab) plus Yervoy (ipilimumab) combination for treatment in adult patients with first-line...

Bristol-Myers Squibb And Flatiron Health Expand Collaboration With A Three-Year Agreement

Bristol-Myers Squibb And Flatiron Health Expand Collaboration With A Three-Year Agreement

Bristol-Myers Squibb (NYSE:BMY) and Flatiron Health, a market leader in oncology-specific electronic health record software and the curation of regulatory-grade real-world data for cancer research and real-world evidence (RWE) generation, expanded their...

4 Keys to Staying Alive in Tough Markets -- And How I'm Playing 3 Big Tech Names

4 Keys to Staying Alive in Tough Markets -- And How I'm Playing 3 Big Tech Names

KLA-Tencor, Microsoft and Intel all report earnings after the close Thursday.

Facebook, Amazon, Microsoft and Ford - 5 Things You Must Know

Facebook, Amazon, Microsoft and Ford - 5 Things You Must Know

U.S. stock futures suggest Wall Street will open with modest gains on Thursday; Facebook posts a blowout quarter; Amazon and Microsoft to report earnings; Ford is no longer a car company.

Global Stocks Mixed, U.S. Futures Soften as Earnings, Oil, Rates Cloud Sentiment

Global Stocks Mixed, U.S. Futures Soften as Earnings, Oil, Rates Cloud Sentiment

Rising oil prices, surging bond yields and mixed earnings forecasts have stalled overnight gains for global stocks and pulled U.S. equity futures into the red ahead of another hectic slate of corporate reports.

Bristol-Myers Squibb Reports First Quarter Financial Results

Bristol-Myers Squibb Reports First Quarter Financial Results

Bristol-Myers Squibb Company (NYSE:BMY) today reported results for the first quarter of 2018 which were highlighted by strong sales for Opdivo , Eliquis , and Orencia, important regulatory progress in Immuno-Oncology and strategic business...

European Commission Approves Bristol-Myers Squibb's Opdivo (nivolumab) Four-Week Dosing Schedule For Advanced Melanoma And Previously Treated Renal Cell Carcinoma

European Commission Approves Bristol-Myers Squibb's Opdivo (nivolumab) Four-Week Dosing Schedule For Advanced Melanoma And Previously Treated Renal Cell Carcinoma

Bristol-Myers Squibb Company (NYSE: BMY) today announced that the European Commission (EC) has approved an every four-week (Q4W) Opdivo (nivolumab) monotherapy dosing schedule of 480 mg infused over 60 minutes as an option for patients with advanced...

Drug Maker Bristol-Myers Squibb Is Having a Bad Reaction to Selling

Drug Maker Bristol-Myers Squibb Is Having a Bad Reaction to Selling

Let's look at the charts this afternoon.

Wendy's, Spirit AeroSystems, Dunkin Brands: 'Mad Money' Lightning Round

Wendy's, Spirit AeroSystems, Dunkin Brands: 'Mad Money' Lightning Round

Jim Cramer highlights Wendy's, Spirit AeroSystems, Dunkin Brands, Bristol-Meyers Squibb, Take-Two Interactive and more.

Self-Inflicted Wounds: Cramer's 'Mad Money' Recap (Tuesday 4/24/18)

Self-Inflicted Wounds: Cramer's 'Mad Money' Recap (Tuesday 4/24/18)

Jim Cramer says it was utter insanity. In earnings, these executives said exactly the wrong things.

Dow Jumps 212 Points as Wall Street Shrugs Off Syria and Turns to Earnings

Dow Jumps 212 Points as Wall Street Shrugs Off Syria and Turns to Earnings

Stocks rise Monday as concerns over prolonged military action in Syria fade and the focus for investors shifts to a heavy upcoming slate of U.S. corporate earnings.

Alkermes Wins Quick Reversal From FDA on Antidepressant Drug

Alkermes Wins Quick Reversal From FDA on Antidepressant Drug

Two weeks ago, the agency told Alkermes it needed more trials for antidepressant drug candidate ALKS-5461. The agency, however, had a change of heart, sending shares jumping on the news.

Jim's Daily Rundown

Today, Jim discusses Raytheon, tensions in Syria, bank earnings, Kohl's, Nordstrom and more!

Merck Notches Key Win Over Bristol-Myers on Lung Cancer Study Data

Merck Notches Key Win Over Bristol-Myers on Lung Cancer Study Data

The drugmakers on April 16 released data from their respective studies at the Association for Cancer Research's annual meeting in Chicago.

U.S. Senator Cory Booker Criticizes Pharma Companies in New Tax Report

U.S. Senator Cory Booker Criticizes Pharma Companies in New Tax Report

The Trump Administration cut corporate taxes and U.S. Senator Cory Booker hoped pharma companies would cut drug prices. That didn't happen and Booker's new analysis hammers those drug companies.

Jim Cramer: Possible Jarring Events Will Be Hard for the Market to Ignore

Jim Cramer: Possible Jarring Events Will Be Hard for the Market to Ignore

Let's puzzle over Syria and the possibility of another 'Saturday Night Massacre.'

Syria Crisis Doesn't Affect Bristol-Myers (It Could Help Amazon): Cramer Insider

Syria Crisis Doesn't Affect Bristol-Myers (It Could Help Amazon): Cramer Insider

If President Trump is too busy to post anti-Amazon tweets, that's good news for the online retailer.

Jim Cramer: Fed Minutes and Oil Hit the Market

Jim Cramer: Fed Minutes and Oil Hit the Market

Why you can't blame the president for Wednesday's weakness.

Jim Cramer: The Fundamentals on the Eve of Earnings Seem Pretty Darned Good

Jim Cramer: The Fundamentals on the Eve of Earnings Seem Pretty Darned Good

But If you want to know what I think could work the loudest here? How about Amazon?

Why Uber's Self-Driving Car Fatality Won't End Autonomous Driving

Why Uber's Self-Driving Car Fatality Won't End Autonomous Driving

The fatality that came at the hands of a self-driving Uber vehicle was tragic. But keep in mind, self-driving cars will be safer than human drivers in the not-too-distant future.

Bristol-Myers Squibb To Hold Investor Event To Discuss AACR Highlights

Bristol-Myers Squibb To Hold Investor Event To Discuss AACR Highlights

Bristol-Myers Squibb Company (NYSE: BMY) will hold an investor event on Monday, April 16, 2018 at 6:00 p.

Alkermes Surprised, Angered by FDA Rejection of Antidepressant

Alkermes Surprised, Angered by FDA Rejection of Antidepressant

Alkermes says the rejection of antidepressant drug ALKS 5461 is a head-scratcher, and it's calling for a prompt meeting with the regulator to get to the bottom of the decision.

FINAL DEADLINE ALERT: Brower Piven Reminds Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Bristol-Myers Squibb Company To Contact The Firm

FINAL DEADLINE ALERT: Brower Piven Reminds Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Bristol-Myers Squibb Company To Contact The Firm

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Northern District of California on behalf...

Women's History Month: Nancy Lieberman -- Still Law Firm's Youngest Partner Ever

Women's History Month: Nancy Lieberman -- Still Law Firm's Youngest Partner Ever

For Women's History Month, Alpha Rising sat down with Nancy Lieberman, Of Counsel at Skadden, Arps. She was and still is the youngest person to ever make partner at her firm. She has worked on some of the biggest M&A deals in history -- and we should mention -- she's in a wheelchair and barely as use of her hands. Feel like a slacker yet? Good. Watch.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses On Their Investment In Bristol-Myers Squibb Company Of Class Action Lawsuit And Upcoming Deadline - BMY

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses On Their Investment In Bristol-Myers Squibb Company Of Class Action Lawsuit And Upcoming Deadline - BMY

Pomerantz LLP announces that a class action lawsuit has been filed against Bristol-Myers Squibb Company ("Bristol-Myers" or the "Company") (NYSE:BMY) and certain of its officers.

TheStreet Quant Rating: C+ (Hold)